<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882488</url>
  </required_header>
  <id_info>
    <org_study_id>HDZ-KA_020_TR</org_study_id>
    <nct_id>NCT04882488</nct_id>
  </id_info>
  <brief_title>Correlation of FFR and iFR With Cardiac PET Perfusion in Patients With Severe Aortic Valve Stenosis</brief_title>
  <acronym>TAVI PET</acronym>
  <official_title>Correlation of FFR and iFR With Cardiac PET Perfusion (at Rest and Under Adenosine) in the Evaluation of Intermediate Coronary Stenoses in Patients With Severe Aortic Valve Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart and Diabetes Center North-Rhine Westfalia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart and Diabetes Center North-Rhine Westfalia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aortic valve stenosis (AS) affects 2-7% of persons &gt; 65 years, symptoms include: angina and&#xD;
      dyspnea, dizziness and syncope. Coincidence of coronary artery disease (CAD), also presenting&#xD;
      with angina and dyspnea, in patients with AS between 40 - 65% . Angina in AS caused by&#xD;
      significant reduction of coronary flow reserve (CFR). CFR is the ratio of maximal flow&#xD;
      increase in the coronary vessel bed during maximal hyperaemia (medically or exercise&#xD;
      induced). FFR (fractional flow reserve) use in patients with AS potentially invalid due to&#xD;
      dysfunctional CFR leading to potential undertreatment of CAD in these patients.CFR&#xD;
      disturbance in AS mainly due to myocardial overload causing concentric hypertrophy, increased&#xD;
      oxygen consumption and neurohormonal activation leading to increased vascular resistance.&#xD;
      Current studies are investigating the validity of FFR and iFR in AS patients. Recent data&#xD;
      demonstrate very good correlation between FFR and iFR derived values to PET myocardial&#xD;
      perfusion imaging values in patients with no evidence of AS. Our study aims to investigate&#xD;
      the diagnostic performance of FFR and iFR in intermediate-grade coronary stenosis in patients&#xD;
      with severe aortic valve disease and correlate FFR- and iFR derived values with those&#xD;
      extracted from PET-perfusion Imaging.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of PET-CT Prior to TAVI and 3 months after TAVI procedure</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of FFR-negative intermediary coronary stenoses in Patients with severe Aortic Stenosis Prior and 3 months following TAVI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Evaluation Prior to and following TAVI</measure>
    <time_frame>3 months</time_frame>
    <description>Angina prevalence in patients with intermediate coronary Stenosis Prior to and 3 months following TAVI</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Coronary Artery Disease</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      NT pro BNP,&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe aortic Stenosis eligible for transcatheter aortic Valve Implantation&#xD;
        (TAVI) with concurring coronary artery disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with severe aortic Stenosis eligible for transcatheter aortic stenosis&#xD;
&#xD;
          -  left ventricular ejection fraction &gt; 55%&#xD;
&#xD;
          -  no intolerance of Adenosin&#xD;
&#xD;
          -  no history of bradycardia, atrioventricular Blockade&#xD;
&#xD;
          -  intermediate coronary Stenosis with FFR&gt; 0.8&#xD;
&#xD;
          -  Age &gt;65&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intolerance of Adenosin&#xD;
&#xD;
          -  left ventricular ejection fraction &lt; 55%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Rudolph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanja Rudolph, MD</last_name>
    <phone>+495731971258</phone>
    <email>trudolph@hdz-nrw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid Kleemeyer</last_name>
    <phone>+49495731971258</phone>
    <email>akleemeyer@hdz-nrw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum, NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>NRW</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tanja K Rudolph, MD</last_name>
      <phone>00495731971258</phone>
      <email>trudolph@hdz-nrw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>PET-CT</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>FFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

